[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-acute-covid-19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-acute-covid-19":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,77,105,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100510443","phase-2-safety-and-efficacy-of-anakinra-treatment-for-patients-with-post-acute-covid-syndrome-100510443",false,"NCT05926505","Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome","Safety and Efficacy of Anakinra Treatment for Patients With Persistent Respiratory Symptoms Post Acute Covid and Immune System Activation: the Precision Double-blind, Randomized Clinical Trial","PRECISION","Inclusion Criteria:\n\n1. Age equal to or above 18 years\n2. Male or female gender\n3. In the case of women of childbearing age and men, an adequate method of contraception should be used during the study. Contraception should be maintained for at least a period of 3 months after the discontinuation of treatment. As an adequate method of contraception, it is suggested: -male or female condom with or without spermicide -contraceptive cap, a diaphragm or contraceptive sponge with a spermicide Prior to admission to the study, a pregnancy test will be performed to exclude pregnancy to women of childbearing age.\n4. Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation in the Member State where the trial is planned.\n5. History of confirmed COVID-19 infection the last 90 days or more\n6. Symptoms compatible with PACS (defined as at least one positive answer to the questionnaire for restriction of daily activities) lasting for more than 2 months\n7. Serum levels of IP-10 more than 250 pg\u002Fml\n8. Presence of ONE of the following two clinical conditions: Condition 1: Impaired Lung Function tests (defined as: DLCOcor \\\u003C76% AND TLC and\u002For FVC lower than 80% of predicted) Condition 2: At least a total radiology score in HRCT more than 20 OR walking of a distance less than 500m in the 6-minute walk test\n\nIf patients meet the criteria for both Conditions 1 and 2, they will be considered for randomization and evaluation for the primary endpoint as in Condition 1.\n\nExclusion Criteria:\n\n1. Age below 18 years\n2. Denial for written informed consent\n3. Any stage IV malignancy\n4. Any primary immunodeficiency\n5. Less than 1,500 neutrophils\u002Fmm3\n6. Known hypersensitivity to anakinra\n7. Known lung fibrosis prior to COVID-19\n8. Medical history of pulmonary hypertension or chronic heart failure\n9. Known chronic obstructive pulmonary disease GOLD stage 3 or 4 prior to COVID-19\n10. Known active tuberculosis (under treatment) or latent tuberculosis (by positive tuberculin test)\n11. Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg\u002Fkg prednisone for a period greater than the last 15 days.\n12. Any anti-cytokine biological treatment the last one month\n13. Severe hepatic failure defined as Child-Pugh stage of 3\n14. End-stage renal failure necessitating hemofiltration or peritoneal hemodialysis\n15. Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study\n16. Participation in any other interventional trial","ALL","18 Years",{"count":20,"type":21},182,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the \"Score of PACS progression reversal\"",[28,29,30],"Post-Acute COVID-19 Syndrome","Post-Acute COVID-19","Long COVID",[32,30,29,33,15,12],"COVID-19","Anakinra","RECRUITING","2026-01-06",{"date":37,"type":38},"2026-01-08","ACTUAL",{"date":40,"type":38},"2023-09-06",{"date":42,"type":21},"2028-03",{"name":44,"class":45},"Hellenic Institute for the Study of Sepsis","OTHER",24,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100603713","long-covid-19-alleviation-through-learning-mindfulness-study-100603713","NCT07140094","Long-Covid-19 Alleviation Through Learning Mindfulness Study","Long-Covid-19 Alleviation Through Learning Mindfulness Study (LONG-CALM)","LONG-CALM","Inclusion Criteria:\n\n* Age \\> or = 18\n* Willing and able to provide informed consent\n* Access to the internet\n* Self-reported history of SARS-CoV-2 infection\n* Current symptoms attributed to PASC by participant or by participant's medical provider; ongoing symptoms that persisted \\>= 12 weeks after Covid-19 illness\n\nExclusion Criteria:\n\n* Participating in another clinical trial of an intervention for PASC symptoms\n* Engaged in a structured MBI",true,{"count":57,"type":21},400,[59],"NA","This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Long COVID symptoms, and improve quality of life among people living with Long COVID. The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. People who decide to take part will be randomly assigned to receive the study mindfulness intervention immediately after joining the study or to receive the study mindfulness intervention 8 weeks after joining the study. All participants will continue their usual medical care. Participants will complete online surveys to measure symptoms over time. The study will last 6 months.",[30,62,29,28,63,64],"Long Covid19","Post-Acute COVID-19 Infection","COVID Long-Haul",[66],"Covid","2025-08-21",{"date":69,"type":38},"2025-08-24",{"date":71,"type":38},"2024-05-21",{"date":73,"type":21},"2027-11-21",{"name":75,"class":45},"Columbia University",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":76},"100505866","ventilatory-and-perfusion-abnormalities-in-individuals-with-post-acute-sequelae-of-sars-cov-2-infection-100505866","NCT05866952","Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection","Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection","PASC VQ","Inclusion Criteria:\n\n* Age ≥ 18\n* Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \\> 3 months ago or no previous history of SARS-CoV-2 infection (control group only)\n* Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs)\n* New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)\n\nExclusion Criteria:\n\n* SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months\n* Inability to provide consent or non-English speaking\n* Pregnancy\n* Any respiratory infection in last 4 weeks\n* PFT relative contraindications\n* History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism\n* Active malignancy undergoing treatment or history of malignancy involving the lung","99 Years",{"count":87,"type":21},40,"OBSERVATIONAL","Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations",[29,91,92,93],"Post COVID-19 Condition","Post Viral Fatigue","Dyspnea",[95],"Ventilation Perfusion Mismatch","2025-07-16",{"date":98,"type":38},"2025-07-20",{"date":100,"type":38},"2023-06-05",{"date":102,"type":21},"2026-12-31",{"name":104,"class":45},"Tufts Medical Center",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100496559","cohort-follow-up-of-epidemic-and-neuroimaging-for-patients-during-the-1st-wave-of-the-covid-19-in-china-100496559","NCT05745805","Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China","Inclusion Criteria:\n\nConfirmed diagnosis of mild Covid-19 (WHO criteria)\u002FConfirmed diagnosis of moderate Covid-19 (WHO criteria)\u002FHealthy people who have not had COVID-19\n\nExclusion Criteria:\n\nHistory of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc. Participants with indication for MRI studies","65 Years",{"count":113,"type":21},600,"Our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the COVID-19. Besides, we aim to establish a database of post-COVID-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long COVID and prevent the neurological symptoms evolution, optimize the tactics of management in China.",[32,116,117,29],"Post-COVID-19 Syndrome","Acute COVID-19",[32,116,119,120,121],"Neuroimaging","Epidemic","Simultaneous Cortico-Spinal Magnetic Resonance Imaging","2023-02-24",{"date":124,"type":38},"2023-02-27",{"date":126,"type":38},"2023-01-12",{"date":128,"type":21},"2026-09-12",{"name":130,"class":45},"First Affiliated Hospital Xi'an Jiaotong University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":76},"100486158","post-covid-condition-cohort-evolution-of-symptomatology-patient-profile-and-associated-prognostic-factors-100486158","NCT05610436","Post-Covid Condition Cohort: Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors","Post-Covid Condition Monitoring Cohort: Evaluation of the Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors","SYNPOCov","Inclusion Criteria:\n\n* outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition\n\nExclusion Criteria:\n\n* patient opposing the processing for research purposes of their data collected in routine care for their care",{"count":140,"type":21},500,"The aim of our cohort is to collect prospectively, in a standardized and exhaustive manner, the health data of patients referred to the CAPCoV, our holistic referal post covid clinics for post-covid condition in order to be able to identify typical profiles of patients suffering from post covid syndrome and to follow the evolution of their disease over time.",[30,29,143],"Post-Acute COVID19 Syndrome","2022-11-08",{"date":146,"type":38},"2022-11-09",{"date":148,"type":38},"2022-01-07",{"date":150,"type":21},"2026-06",{"name":152,"class":45},"Central Hospital, Nancy, France"]